Zafin (Paracetamol & Tramadol) (30 Tabs)
|Zafin (Paracetamol & Tramadol) (30 Tabs)x3||$26.9||$80.70|
|Zafin (Paracetamol & Tramadol) (30 Tabs)x6||$22.9||$137.40|
|Zafin (Paracetamol & Tramadol) (30 Tabs)x9||$19.9||$179.10|
ZAFIN (30 TABS)
Zafin contains a combination of Tramadol (Zafin) and acetaminophen. Tramadol (Zafin) is a narcotic-like pain reliever. Acetaminophen is a less potent pain reliever that increases the effects of Tramadol (Zafin). Zafin is used to treat moderate to severe. Zafin may also be used for purposes not listed in this medication guide.
How to use
Use Zafin as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Take Zafin by mouth with or without food.
Do not take Zafin for more than 5 days unless advised to do so by your doctor.
Do not take more than 8 tablets per day. Do not take more than 4 tablets per day if you have kidney problems.
If you miss a dose of Zafin and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Zafin.
Common adverse reactions reported in clinical trials are constipation, nausea, diarrhea, dry mouth, psychiatric disorders, somnolence, anorexia, insomnia, dizziness, increased sweating, pruritus, prostatic disorder.
Drug Abuse and Dependence: Abuse: Tramadol (Zafin) has mu-opioid agonist activity. Zafin, a tramadol-containing product, can be abused and may be subject to criminal diversion.
Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial and environmental factors influencing its development and manifestations. Drug addiction is characterized by behaviors that include 1 or more of the following: Impaired control over drug use, compulsive use, use for non-medical purposes, continued use despite harm or risk of harm and craving. Drug addiction is a treatable disease, utilizing a multidisciplinary approach, but relapse is common.
“Drug-seeking” behavior is very common in addicts and drug abusers. Drug-seeking tactics, include emergency calls or visits near the end of office hrs, refusal to undergo appropriate examination, testing or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping” to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction.
Abuse and addiction are separate and distinct from physical dependence and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of Tramadol (Zafin) HCl and acetaminophen tablets can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances.
Concerns about abuse and addiction should not prevent the proper management of pain. However, all patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.
Proper assessment of the patient and periodic re-evaluation of therapy are appropriate measures that help to limit the potential abuse of Zafin.
Zafin are intended for oral use only.
Dependence: Tolerance is the need for increasing doses of drugs to maintain a defined effect eg, analgesia (in the absence of disease progression or other external factors). Physical dependence is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist.
The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: Restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia and mydriasis. Other symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea or increased blood pressure, respiratory rate or heart rate.
Generally, tolerance and/or withdrawal are more likely to occur the longer a patient is on continuous therapy with Zafin.
Adults and Children >16 years: 1-2 tablets every 4-6 hrs as needed for pain relief up to a maximum of 8 tablets/day.
Children: The safety and effectiveness of Zafin has not been studied in the pediatric population (<16 years). Therefore, treatment is not recommended in this population.
Elderly: Elimination of the active components may be prolonged in elderly patients >75 yrs. Therefore, if necessary the dosage interval may be extended according to the patients requirements.
Renal/Dialysis/Hepatic Insufficiency: The pharmacokinetics of the tramadol/paracetamol combination in patients with renal impairment have not been studied. Experience with Tramadol (Zafin) suggests that impaired renal function results in a decreased rate and extent of excretion of Tramadol (Zafin). In patients with creatinine clearance of <30 mL/min, it is recommended that the dosing interval of Zafin be increased not to exceed 2 tablets every 12 hrs. The pharmacokinetics and tolerability of Zafin in patients with impaired hepatic function has not been studied. Tramadol (Zafin) and Paracetamol (Zafin) are both extensively metabolized by the liver. The use of Zafin in patients with severe hepatic impairment is not recommended.
The tablets should be taken whole, not divided or chewed, with sufficient liquid, without regard to food.
Zafin should under no circumstances be administered for longer than absolutely necessary. If long-term pain treatment with Zafin is necessary in view of the nature and severity of the illness, then careful and regular monitoring should be carried out (if necessary with breaks in treatment) to establish whether and to what extent further treatment is necessary.